Treatment of small cell lung cancer

Research output: Contribution to journalArticle

Abstract

Treatment of small cell lung cancer (SCLC) remains a significant challenge for the oncologists. Attempts to improve the results of first-line treatment have all failed so far and no real progress has been made in last years, emphasizing the need for novel strategies of treatment and the development of validated biomarkers. Patients with limited disease and good performance status should be considered for concomitant chemoradiotherapy, followed by prophylactic cranial irradiation. Patients with extensive disease should be treated with a platinum-based chemotherapy (cisplatin or carboplatin); chest radiotherapy can be considered in patients achieving extra-thoracic complete response and prophylactic cranial irradiation is recommended for patients responsive to initial chemotherapy. A large number of molecular-targeted drugs and immunomodulators are currently in clinical development: however, only a better understanding of molecular biology of SCLC and the identification of molecular markers predictive of response to targeted agents will lead to advances in the treatment of SCLC.

Original languageEnglish
Pages (from-to)257-270
Number of pages14
JournalCritical Reviews in Oncology/Hematology
Volume91
Issue number3
DOIs
Publication statusPublished - 2014

Keywords

  • Chemotherapy
  • Immunomodulators
  • Radiotherapy
  • Small cell lung cancer
  • Targeted agents

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Treatment of small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this